Making a dagger or giant knife fit for 2020 with a real murder hornet cast in epoxy resin. This project embodies a unique ...

UBS remains bullish on Eli Lilly’s future thanks to surging demand for its obesity and diabetes treatments. UBS predicts Zepbound sales could exceed market expectations by roughly 15%. Meanwhile, ...

Eli Lilly & Company (NYSE:LLY) ranks among the best set-it-and-forget-it stocks to buy. On June 27, UBS kept its Buy rating ...

CVS says the decision to cover Wegovy and exclude Zepbound is "forcing the drug manufacturers to compete with one another" and will encourage both Eli Lilly and Novo Nordisk to lower prices for their ...

This change is happening because there’s another covered medication that’s safe and effective for your condition and may cost ...

Jury reaches partial verdict in Sean Combs trial, unable to reach verdict on Count One Republican Senator tells House not to ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

CVS adds Wegovy to its top formularies and bolsters its Weight Management program, aiming to expand access while cutting costs.

Questions included whether the Indianapolis-based drugmaker is working to improve insurance coverage for the drug and highlighted users’ concerns about comparisons with Novo Nordisk's Wegovy.

Eli Lilly and Company (NYSE:LLY) may be affected by the CVS formulary change considering it could change how its medication, ...